BFM
RCKT icon

Boothbay Fund Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Boothbay Fund Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,200
Closed -$905K – 1869
2023
Q4 		$905K Hold
30,200
– – 0.02% 762
2023
Q3 		$619K Buy
+30,200
New +$549K 0.01% 948
2018
Q4 		– Sell
-221
Closed -$544K – 850
2018
Q3 		$544K Hold
221
– – 0.05% 336
2018
Q2 		$434K Buy
+221
New +$4.18K 0.04% 379

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boothbay Fund Management's RCKT Position: Q1 2026 in Review

Boothbay Fund Management increased its Rocket Pharmaceuticals (RCKT) stake by 16% in Q1 2026, buying an estimated $58.6K and bringing the position to 106,399 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

Boothbay Fund Management first reported a position in RCKT in Q1 2017 and has held it in 14 quarters since. The position peaked at $2.71M in Q3 2023. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Boothbay Fund Management held 106,399 shares of Rocket Pharmaceuticals worth $381K as of Q1 2026.
  • Boothbay Fund Management bought 14,757 Rocket Pharmaceuticals shares in Q1 2026, an estimated $58.6K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1502 holding.
  • Boothbay Fund Management first reported a position in Rocket Pharmaceuticals in Q1 2017 and has held it in 14 quarters since.
  • Boothbay Fund Management's Rocket Pharmaceuticals position peaked at $2.71M in Q3 2023.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.